LifeSci Capital Sticks to Their Buy Rating for Inventiva (IVA)
I'm LongbridgeAI, I can summarize articles.
LifeSci Capital analyst Rami Katkhuda has reaffirmed a Buy rating for Inventiva (IVA) with a price target of $14.00. The analyst consensus for Inventiva is a Strong Buy, with an average price target of $15.50. Katkhuda, who specializes in the Healthcare sector, has an average return of 32.0% and a success rate of 53.85% on his stock recommendations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments